<?xml version="1.0" encoding="UTF-8"?>
<p id="Par41">Kim et al. published a case report of four patients who developed neurological manifestations during treatment of MERS. A triple antiviral treatment, consisting of subcutaneous pegylated interferon alpha-2a, high-dose oral ribavirin and oral lopinavir/ritonavir, was administered to all patients in the concerned hospital. Characteristics, presentation and diagnosis of the reported patients experiencing neurological symptoms during their treatment of MERS-CoV-infection are summarized in TableÂ 
 <xref rid="Tab3" ref-type="table">3</xref> [
 <xref ref-type="bibr" rid="CR39">39</xref>].
</p>
